AGENUS INC (AGEN) research
AGENUS INC- Sector
- Biotechnology
- Last price
- $7.85
- As of
AGENUS INC (AGEN): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-18.
As of . Source: SEC EDGAR filings for AGEN. Method and limitations.
Share the AGEN intelligence card
See AGEN live in the terminal
Track AGEN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live AGEN terminal, freeActive signals for AGEN
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +88% to AGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +171% to AGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +88% to AGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +171% to AGEN (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 119.6%, EPS $-0.01 vs $0.051 estimate
FREE, NO ACCOUNT
Every signal on AGEN, as it fires
You are seeing 5 of 12 signals recorded on AGEN since 2026-06-21.
The five above landed across 2 days. The other 7 were recorded on 2 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AGEN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00847G804 · 2026Q2 | $699K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00847G804 · 2026Q2 | $302K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AGEN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AGEN against its peers
AGEN's operating margin of -17.7% ranks in the 79th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | AGEN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 114M USD | 30.9M USD | 89 | 13 |
| Operating margin | -17.7% | -279.5% | 79 | 11 |
| Net margin | -2.7% | -213.4% | 81 | 12 |
| Return on equity | n/a | -42.2% | n/a | 15 |
Peers (18): IFRX, VNDA, FATE, ABEO, QTTB, SABS, ZNTL, UPB, OBIO, SION, IMRX, CYDY, EYPT, FHTX, STRO, IPSC, PYXS, IKT. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AGEN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AGEN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AGENand get the insider, 13F, options, and confluence read in one view.